Royalty Pharma (RPRX)
(Delayed Data from NSDQ)
$27.54 USD
-0.45 (-1.61%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $27.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
Income Statements
Fiscal Year end for Royalty Pharma PLC falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2,355 | 2,237 | 2,289 | 2,122 | 1,814 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 2,355 | 2,237 | 2,289 | 2,122 | 1,814 |
Selling & Adminstrative & Depr. & Amort Expenses | 862 | 1,930 | 859 | 527 | -809 |
Income After Depreciation & Amortization | 1,492 | 307 | 1,431 | 1,595 | 2,623 |
Non-Operating Income | 395 | 111 | -23 | 264 | 107 |
Interest Expense | 187 | 188 | 166 | 157 | 269 |
Pretax Income | 1,700 | 230 | 1,241 | 1,702 | 2,461 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 565 | 187 | 621 | 727 | 113 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 1,700 | 230 | 1,241 | 1,702 | 2,461 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 1,135 | 43 | 620 | 975 | 2,349 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 1,513 | 334 | 1,474 | 1,630 | 2,660 |
Depreciation & Amortization (Cash Flow) | 21 | 27 | 43 | 35 | 37 |
Income After Depreciation & Amortization | 1,492 | 307 | 1,431 | 1,595 | 2,623 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 603.00 | 607.00 | 607.00 | 607.00 | NA |
Diluted EPS Before Non-Recurring Items | 4.49 | 3.68 | 2.91 | 1.61 | NA |
Diluted Net EPS (GAAP) | 2.53 | 0.10 | 1.49 | 1.32 | NA |
Fiscal Year end for Royalty Pharma PLC falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 537.27 | 567.98 | 596.07 | 536.31 | 538.20 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 537.27 | 567.98 | 596.07 | 536.31 | 538.20 |
SG&A, R&D, and Dept/Amort Expenses | 267.64 | 641.75 | -16.83 | 384.87 | 289.36 |
Income After SG&A, R&D, and Dept/Amort Expenses | 269.63 | -73.77 | 612.90 | 151.44 | 248.84 |
Non-Operating Income | -26.24 | 113.73 | 151.95 | 16.67 | 149.45 |
Interest Expense | 49.01 | 44.23 | 47.25 | 46.03 | 46.95 |
Pretax Income | 194.38 | -4.27 | 717.59 | 122.08 | 351.34 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 92.37 | -9.05 | 223.25 | 49.96 | 123.71 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 194.38 | -4.27 | 717.59 | 122.08 | 351.34 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 102.00 | 4.78 | 494.34 | 72.11 | 227.63 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 597.00 | 597.00 | 598.00 | 601.00 | 606.00 |
Diluted EPS Before Non-Recurring Items | 0.96 | 0.98 | 1.15 | 0.79 | 0.85 |
Diluted Net EPS (GAAP) | 0.23 | 0.01 | 1.11 | 0.16 | 0.50 |